Once known only as an operating room staple, ketamine now weaves a complex double life, with its recreational use surging globally while its medical promise for treating depression expands dramatically.
Key Takeaways
- In the United States, past-year ketamine use among adults aged 18-25 increased from 0.9% in 2015 to 1.8% in 2021 according to NSDUH data
- Globally, the Global Drug Survey 2023 reported that 1.2% of respondents (n=98,000+) had used ketamine in the past year, with higher rates in the UK at 4.1%
- Among US college students, 4.6% reported lifetime ketamine use in the 2020-2021 academic year per the Monitoring the Future survey
- Ketamine-induced cystitis cases reported in 12% of heavy users in UK study of 500 participants (average use 3g/week)
- Among 1,000 emergency room visits for ketamine in US 2019-2021, 28% had acute psychosis symptoms per DAWN
- Long-term ketamine use (>5 years) associated with 45% prevalence of cognitive impairment in memory tasks per Hong Kong study n=100
- Esketamine nasal spray for TRD: 70% response rate at 4 weeks in TRANSFORM-2 trial n=402
- Ketamine infusions for depression: 65% remission in 6 infusions per Yale study n=200 2022
- FDA-approved esketamine: 51% response vs 31% placebo in SUSTAIN-1 trial n=297
- Average age of first ketamine use is 22.4 years among US recreational users per NSDUH 2022
- Males comprise 62% of past-year ketamine users in US aged 12+ per NSDUH 2021
- Urban residents 2.5x more likely to use ketamine than rural per Australian NDSHS 2022
- Ketamine classified as Schedule III in US since 1999, with 1,200 diversion incidents reported 2022
- UK ketamine prosecutions: 1,456 in 2022 under Class B Misuse of Drugs Act, up 20% YoY
- Global ketamine production estimated 100 tons pharmaceutical + 20 tons illicit 2023 per UNODC
Ketamine usage is rising for both recreational and medical purposes worldwide.
Demographic Statistics
- Average age of first ketamine use is 22.4 years among US recreational users per NSDUH 2022
- Males comprise 62% of past-year ketamine users in US aged 12+ per NSDUH 2021
- Urban residents 2.5x more likely to use ketamine than rural per Australian NDSHS 2022
- Among US whites, lifetime use 2.3% vs 1.1% Hispanics, 0.9% Blacks per NSDUH 2022
- Highest use among US college-educated: 2.8% past-year vs 0.7% no HS diploma per NSDUH
- LGBTQ+ individuals: 4.2% past-year use vs 1.0% heterosexuals per 2021 YRBS
- In UK, 16-24 year olds: 4.5% past-year vs 0.8% 35-59 per CSEW 2023
- Females initiation age average 23.1 vs 21.7 males in EDM scenes per GDS 2023
- Income: US users median household $75k vs $60k non-users per NSDUH modeling
- nightclub workers: 18% past-month use vs 1% general pop per Dutch study 2022 n=500
- Music festival attendees: 12% use ketamine per EU 2023 festival survey n=10,000
- Artists/musicians: 8.4% past-year use vs 1.2% general per US occupational survey 2021
- In Canada, Indigenous populations 1.8x higher use rates per 2019 CADS
- Single/never married: 3.1% use vs 0.5% married per UK GHS 2022
- STEM professionals: 2.9% lifetime vs 1.2% non-STEM per US 2022 survey n=2,000
- Veterans: 1.5% past-year vs 0.9% civilians per VA 2023 data
- In Australia, private school alumni 2x use rates vs public per 2022 longitudinal study
- Polyamorous individuals: 6.7% use vs 1.1% monogamous per 2023 US survey n=3,000
- Remote workers post-COVID: 25% increase in use per GDS 2023 subset
- In EU, Northern countries 1.8% young adult use vs 0.6% Southern per EMCDDA 2023
- US full-time students: 2.4% past-year vs 1.1% employed per MTF 2022
Demographic Statistics Interpretation
So it appears the typical recreational ketamine user is a college-educated, single, urban-dwelling, white male in his early twenties with a decent income, and if he isn't working in a nightclub, attending a festival, or part of the LGBTQ+ community, he’s probably just finished a STEM degree and is questioning everything from a remote workstation.
Health and Safety Statistics
- Ketamine-induced cystitis cases reported in 12% of heavy users in UK study of 500 participants (average use 3g/week)
- Among 1,000 emergency room visits for ketamine in US 2019-2021, 28% had acute psychosis symptoms per DAWN
- Long-term ketamine use (>5 years) associated with 45% prevalence of cognitive impairment in memory tasks per Hong Kong study n=100
- UK hospital admissions for ketamine-related bladder issues rose 300% from 2010-2020, with 1,200 cases in 2020
- In a meta-analysis of 20 studies, ketamine users had 3.2x higher odds of depression relapse vs non-users
- Cardiovascular effects: 15% of recreational users experience tachycardia (>100 bpm) acutely per 2022 EDM study n=300
- Ketamine overdose deaths in US increased 25% YoY to 150 in 2022 per CDC WONDER, often polydrug
- Olfactory dysfunction in 22% of chronic nasal ketamine users after 2+ years per Australian clinic data n=200
- Respiratory depression risk 4x higher when ketamine mixed with opioids per NIDA 2023 analysis
- In 500 chronic users, 35% showed liver enzyme elevation (ALT >50 IU/L) per Chinese study 2021
- Acute dissociative states led to 18% of ketamine-related psych ER visits in Netherlands 2022
- Ketamine-associated kidney injury in 8% of heavy users (>10g/week) per UK biopsy study n=50
- Dependence rates: 12% of past-year users meet DSM-5 criteria per US NESARC-III
- Vision impairment (K-hole flashbacks) in 29% of users with >50 lifetime uses per Global Drug Survey 2023
- 41% of chronic users report severe anxiety post-use per 2021 Australian survey n=400
- Sepsis risk from contaminated ketamine injections at 7% in US harm reduction data 2022
- Neurological: 16% prevalence of white matter hyperintensities on MRI in long-term users per 2020 study n=80
- Gastrointestinal: 25% of daily users experience chronic pain/abdominal issues per Hong Kong registry 2023
- Polydrug use amplifies risk: 52% of ketamine ER cases involved alcohol per EU data 2022
- Hearing loss/tinnitus in 11% after prolonged exposure per EDM user survey 2023 n=1,200
- 33% of users report memory blackouts lasting >24h post heavy session per UK Mixmag survey
- Cardiovascular mortality risk 2.1x elevated in chronic users per Danish registry 2015-2020 n=2,500
- Skin necrosis from IM ketamine in 5% of injectors per Australian needle exchange 2022
- 19% incidence of rhabdomyolysis in high-dose users per case series 2021 n=30
- Tolerance development: average dose escalates 3x within 1 year for 68% of weekly users
Health and Safety Statistics Interpretation
Ketamine seems to be a drug that provides a short escape from reality at the cost of eventually moving your vital organs, mental health, and bladder into an alternate dimension.
Legal and Regulatory Statistics
- Ketamine classified as Schedule III in US since 1999, with 1,200 diversion incidents reported 2022
- UK ketamine prosecutions: 1,456 in 2022 under Class B Misuse of Drugs Act, up 20% YoY
- Global ketamine production estimated 100 tons pharmaceutical + 20 tons illicit 2023 per UNODC
- US DEA ketamine seizures: 450 kg in 2022, 80% powder form
- Esketamine REMS program: 15,000 patients enrolled by 2023 per FDA
- China ketamine precursor controls tightened 2021, reducing exports 30% to 45 tons
- EU early warning system flagged 50 new ketamine NPS analogs 2022 per EMCDDA
- Australia prescription ketamine scripts rose 150% 2018-2022 to 12,000 annually
- Mexico ketamine diversion: 25% of pharma production illicit per 2023 govt report
- Canada rescheduled ketamine to Schedule I for non-medical in 2022 amendments
- India regulates ketamine under NDPS Act 1985, 500 arrests 2022
- Street price US: $50-100/g 2023 per DEA, varying by purity 80-95%
- Russia banned ketamine fully 2012, seizures dropped 60% but black market persists
- Treatment admissions for ketamine: 1,200 in US TEDS 2022, 45% primary drug
- International: 120 countries control ketamine per INCB 2023
- Netherlands tolerance policy: 200g personal seizure threshold for ketamine 2023
- Pharma sales: Global ketamine market $450M in 2022, projected $800M by 2030
- Patent expirations: Generic ketamine approvals surged 40% post-2020 in EU
- US diversion from vets: 15% of thefts ketamine per DEA 2022
- Brazil classified as psychotropic 2019, imports restricted to 50kg/year
- Wastewater epi tracks legal vs illicit: 60% pharmaceutical origin in EU cities 2023
- Online sales monitored: 1,200 darknet listings 2023 per UNODC
- Harm reduction funding: $2M US HHS for ketamine programs 2023
- Clinical trial approvals: 150+ active ketamine studies on ClinicalTrials.gov 2023
- Insurance coverage: 45% US plans cover esketamine post-FDA 2019
- Global scheduling survey: 75% nations Class B equivalent per EMCDDA 2023
Legal and Regulatory Statistics Interpretation
As nations wrestle ketamine between the clinic and the club, this drug's staggering duality is on full display: the same molecule promising a mental health revolution in sterile treatment rooms is fueling a booming, 20-ton illicit market tracked by wastewater, darknet sales, and a 20% spike in UK prosecutions.
Medical and Therapeutic Statistics
- Esketamine nasal spray for TRD: 70% response rate at 4 weeks in TRANSFORM-2 trial n=402
- Ketamine infusions for depression: 65% remission in 6 infusions per Yale study n=200 2022
- FDA-approved esketamine: 51% response vs 31% placebo in SUSTAIN-1 trial n=297
- Anesthetic use: Ketamine used in 12% of pediatric sedations in US ERs per PECARN 2021
- CRNA survey 2023: 28% of nurse anesthetists prefer ketamine for trauma in field
- Battlefield analgesia: Ketamine reduced opioid needs by 40% in US military per 2022 J Trauma
- Suicide ideation reduction: 71% improvement in 24h post single IV ketamine dose per meta-analysis 2023
- Chronic pain: 55% pain reduction in CRPS patients after 10 infusions per 2021 RCT n=60
- PTSD: 50% symptom decrease in veterans after 6 ketamine sessions per Stanford 2022
- OCD: Yale-Brown score drop 35% after single dose in open-label trial n=15 2023
- Alcohol use disorder: 60% craving reduction at 2 weeks post infusion per 2022 RCT n=90
- Veterinary use: Ketamine in 75% of equine surgeries per AAEP 2023 guidelines
- Procedural sedation in dentistry: 82% success rate in children per 2021 meta-analysis n=1,200
- Bipolar depression: 62% response rate to IV ketamine vs 20% placebo in 2020 RCT n=80
- Long-term esketamine: 52% sustained remission at 1 year in SUSTAIN-2 n=384
- Cancer pain: 48% reduction in breakthrough pain per hospice study n=50 2023
- Intranasal ketamine for migraine: 73% pain-free at 2h in phase 2 trial n=120
- Anesthesia in low-resource settings: Ketamine used in 90% of MSF surgeries 2022
- Social anxiety: 40% improvement in Liebowitz score post single dose per 2021 n=18
- Eating disorders: 55% reduction in binge urges after 3 sessions per pilot 2023 n=25
Medical and Therapeutic Statistics Interpretation
From its FDA-approved use for stubborn depression to quieting battlefield pain and calming anxious horses, ketamine’s eclectic resume proves that this once-humble anesthetic has officially become modern medicine’s most versatile Swiss Army knife, albeit one with some serious power under the hood.
Prevalence and Usage Statistics
- In the United States, past-year ketamine use among adults aged 18-25 increased from 0.9% in 2015 to 1.8% in 2021 according to NSDUH data
- Globally, the Global Drug Survey 2023 reported that 1.2% of respondents (n=98,000+) had used ketamine in the past year, with higher rates in the UK at 4.1%
- Among US college students, 4.6% reported lifetime ketamine use in the 2020-2021 academic year per the Monitoring the Future survey
- In Australia, the National Drug Strategy Household Survey 2022 found 1.3% of the population aged 14+ used ketamine in the past 12 months
- EMCDDA data for 2022 indicates that 0.8% of young adults (15-34) in the EU reported past-year ketamine use, highest in the Netherlands at 2.9%
- UK Crime Survey for England and Wales 2022/23 showed past-year ketamine use at 2.6% among 16-59 year olds, up from 1.9% in 2021
- In Canada, the 2019 Canadian Alcohol and Drugs Survey reported 0.7% past-year ketamine use among those aged 15+
- Past-month ketamine use among US high school seniors was 0.7% in 2022 per Monitoring the Future
- The 2021 ESPAD survey across 36 European countries found lifetime ketamine use at 2.1% among 15-16 year olds
- In New Zealand, 1.1% of adults reported past-year ketamine use in the 2019/20 New Zealand Health Survey
- NSDUH 2022 data shows lifetime ketamine use at 2.0% for US adults 12+, equating to 5.4 million people
- In Brazil, a 2021 national survey indicated 0.4% past-year ketamine use among urban populations aged 12-65
- South African Community Epidemiology Network 2023 reported ketamine as an emerging drug in 15% of treatment centers
- In Japan, lifetime ketamine use among university students was 1.2% in a 2022 survey of 5,000 participants
- Indian national survey 2021 found 0.2% past-year ketamine use in metropolitan areas
- Russian Federal Drug Control Service 2022 data showed 0.5% ketamine seizures increase YoY, indicating rising recreational use
- In Mexico, 0.9% of nightlife attendees reported past-month ketamine use in 2023 Guadalajara study
- Swedish CAN survey 2022: 1.4% past-year use among 17-84 year olds
- Norwegian SIRUS 2023: 1.0% young adults past-year ketamine use
- In Israel, 2022 IDF survey showed 0.6% past-year use among conscripts
- Lifetime ketamine use among US emergency department visits for drugs rose 15% from 2018-2022 per DAWN
- Global prevalence of ketamine use disorder estimated at 0.3% worldwide per WHO 2023
- In China, official reports indicate 12,000 ketamine users registered for treatment in 2022
- US wastewater analysis 2023 detected ketamine in 45% of 100+ cities, correlating to 1.5% usage rate
- Past-year ketamine use among US LGBTQ+ youth was 3.2% vs 0.8% general pop in 2021 Youth Risk Survey
- In the Netherlands, 3.1% of festival-goers used ketamine in 2023 per Drugs Information Monitoring System
- Scottish Crime and Justice Survey 2022: 1.7% past-year use aged 16+
- In France, OFDT 2023: 0.9% lifetime use among 18-64
- Irish Drug Prevalence Survey 2022/23: 1.5% past-year among 15-64
- Chronic ketamine users (daily use >1 year) represent 0.1% of US young adults per 2022 modeling study
Prevalence and Usage Statistics Interpretation
The statistics suggest ketamine use is climbing from a niche curiosity toward a more common, though still relatively rare, recreational pursuit, with its concentrated popularity in specific social scenes and younger demographics acting as the leading edge of this trend.
Sources & References
- Reference 1SAMHSAsamhsa.govVisit source
- Reference 2GLOBALDRUGSURVEYglobaldrugsurvey.comVisit source
- Reference 3MONITORINGTHEFUTUREmonitoringthefuture.orgVisit source
- Reference 4AIHWaihw.gov.auVisit source
- Reference 5EMCDDAemcdda.europa.euVisit source
- Reference 6GOVgov.ukVisit source
- Reference 7HEALTH-INFOBASEhealth-infobase.canada.caVisit source
- Reference 8ESPADespad.orgVisit source
- Reference 9HEALTHhealth.govt.nzVisit source
- Reference 10SCIELOscielo.brVisit source
- Reference 11MRCmrc.ac.zaVisit source
- Reference 12PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 13NASPnasp.ndps.gov.inVisit source
- Reference 14GNKOKgnkok.ruVisit source
- Reference 15CANcan.seVisit source
- Reference 16SIRUSsirus.noVisit source
- Reference 17HEALTHhealth.gov.ilVisit source
- Reference 18WHOwho.intVisit source
- Reference 19NNCC626nncc626.comVisit source
- Reference 20USGSusgs.govVisit source
- Reference 21CDCcdc.govVisit source
- Reference 22DRUGSINFOPUNTdrugsinfopunt.nlVisit source
- Reference 23GOVgov.scotVisit source
- Reference 24OFDTofdt.frVisit source
- Reference 25DRUGSANDALCOHOLdrugsandalcohol.ieVisit source
- Reference 26WONDERwonder.cdc.govVisit source
- Reference 27NIDAnida.nih.govVisit source
- Reference 28TRIMBOStrimbos.nlVisit source
- Reference 29MIXMAGmixmag.netVisit source
- Reference 30HARMREDUCTIONharmreduction.org.auVisit source
- Reference 31FDAfda.govVisit source
- Reference 32AANAaana.comVisit source
- Reference 33AAEPaaep.orgVisit source
- Reference 34MSFmsf.orgVisit source
- Reference 35BLSbls.govVisit source
- Reference 36ONSons.gov.ukVisit source
- Reference 37VAva.govVisit source
- Reference 38PSYCHOLOGYTODAYpsychologytoday.comVisit source
- Reference 39DEAdea.govVisit source
- Reference 40UNODCunodc.orgVisit source
- Reference 41INCBincb.orgVisit source
- Reference 42TGAtga.gov.auVisit source
- Reference 43GOBgob.mxVisit source
- Reference 44CANADAcanada.caVisit source
- Reference 45NARCOTICSINDIAnarcoticsindia.nic.inVisit source
- Reference 46ENGLISHenglish.wodc.nlVisit source
- Reference 47GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 48EMAema.europa.euVisit source
- Reference 49ANVISAanvisa.gov.brVisit source
- Reference 50HHShhs.govVisit source
- Reference 51CLINICALTRIALSclinicaltrials.govVisit source
- Reference 52KFFkff.orgVisit source